New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ChromaDex, Glanbia sign distribution deal

ChromaDex, Glanbia sign distribution deal
Glanbia Nutritionals will serve as the exclusive distributor of pTeroPure in North America to the food, beverage and dietary supplement industries.

ChromaDex Corp., an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced a distribution agreement for pTeroPure with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company. Under the terms of the agreement, Glanbia Nutritionals will serve as the exclusive distributor of pTeroPure in North America to the food, beverage and dietary supplement industries.

Pterostilbene is an antioxidant found in blueberries and other berries and believed by many experts to have a number of health benefits. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals). pTeroPure pterostilbene was named as the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.

Along with a number of other effects, pterostilbene has shown to support heart health, cognitive function and anti-aging. Data from the first human clinical trial of pTeroPure pterostilbene showed the compound to be generally safe for human consumption. The safety results were presented at the 6th World Congress on Polyphenols Applications in Paris, France on June 7, 2012. Data analyses from the trial on the effects of pTeroPure on blood pressure, triglycerides, cholesterol and oxidative stress are currently underway, and results are expected to be made public following acceptance in a peer-reviewed journal.

"As an innovative ingredient with impressive scientific support, pTeroPure is an excellent addition to our current product line," said Richard Hazel, CEO of Glanbia Nutritionals. "We're excited to work with ChromaDex to increase their current market presence and introduce pTeroPure into new applications and territories."

Commenting on the announcement, Frank Jaksch, CEO and founder of ChromaDex, stated, "We are looking forward to the national expansion of pTeroPure and its adoption into numerous consumer products. Glanbia, together with its superb sales, marketing and R&D teams, is an ideal partner for ChromaDex. With our recently announced pTeroPure clinical safety results and the forthcoming human efficacy data, Glanbia should be well positioned to bring our exciting novel patented and proven ingredient to the food and beverage, dietary supplement, and animal health markets."


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.